

## DAFTAR PUSTAKA

- Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. *Lab Invest* 1996;74:1105–15.
- Acton QA. *Intercellular Signaling Peptides and Proteins-Advanced in Research and Application*. Scholarly Ed, Atlanta, Georgia. 2013
- Andrijono A. *Sinopsis Kanker Ginekologi*. Divisi Onkologi Departemen Obstetri dan Ginekologi FKUI RSUPN dr. Cipto Mangunkusumo. Jakarta, 2004.
- Bamberger E.S, Perrett C.W. Angiogenesis in epithelial ovarian cancer. *Journal of clinical pathology. Mol Pathol*. 2002 Dec; 55(6): 348–359.
- Bergers G, Benjamin LE. *Nat Rev cancer*. 2003;3:401-410
- Berek J.S, Hacker NF. *Practical gynecologic oncology*, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:443-541
- Berek, J.S., Natarajan, S. Ovarian and Fallopian Tube Cancer. Dalam : Berek, J.S., editors. *Berek & Novak's Gynecology*. 14th Ed. Philadelphia: Lippincott William & Wilkins, 2007:p.1457-1548
- Busmar, B. Kanker Ovarium. In: Aziz, M.F., Andrijono, Saifuddin, A.B., editors. *Buku Acuan Nasional Onkologi*. 1st Ed. Jakarta: Yayasan Bina Pustaka Sarwono Prawirodihardjo, 2006:p. 468-527.
- Cambuzzi E, Lima de R, Teixeira S.L, Pêgas K.L. The relationship between serum levels of CA 125 and the degree of differentiation in ovarian neoplasms. *J Bras Patol Med Lab*, v. 50, n. 1, p. 20-25, fevereiro 2014.
- Cancer Research UK. *Ovarian Cancer*, September 2014.
- Carmeliet P, Collen D. Vascular development and disorders : molecular analysis and pathogenic insights. *Kidney Int*. 1998; 53 : 1519-9
- Cerveira N, Bizzaro N, Teixeira MR. *Cancer Cell Cycle*. Canal BQ No.9. Fevereiro, 2012.
- Chapuli RM, Quesada AR, Medina MA. Angiogenesis and signal transduction in endothelial cell . *Cell. Mol. Life. Sci*. 2004; 61: 2224-43
- Cheng D, Liang B, Li Y. Serum Vascular Endothelial Growth Factor (VEGF-C) as a Diagnostic and Prognostic Marker in Patients with Ovarian Cancer. *PLOS*

ONE. February, 2013 Vol.8.

- Chu CS, Rubin SC. Basic Principles of Chemotherapy. In: DiSaia, Creasman. Clinical Gynecologic Oncology. 7th ed. Elsevier, 2007.
- Cotran & Kumar. 2003. *Robbin : Basic Pathology*: Neoplasia, 7<sup>th</sup> ed Philadelphia:W.B. Saunders Co. p. 165-210
- Duncan TJ, Al-Attar A, Rolland P, et al. Vascular Endothelial Growth Factor Expression in Ovarian cancer : A Model for Targeted Use of Novel Therapies?. Clin Cancer Res 2008;14:3030-3035
- Ezzati M, Abdullah A, Shariffabrizi A, Hou J, et al. Recent Advancements in Prognostic Factors of Epithelial Ovarian carcinoma. Review article. Hindawi Publ. International Scholarly Research Notices, 2014.
- Ferrara N. Vascular Endothelial Growth Factor: Pathophysiology and Clinical Implications. In: Ferrara N. Editor. Angiogenesis from basic science to Clinical applications. Boca Raton: Taylor and Francis Group; 2007. p. 1-16
- Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL: Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006, 247:4-21
- Folkman J, Shing Y. Angiogenesis. J. Biol. Chem. 1992;267(16):10931-34
- Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H. Pathophysiology of Tumor Neovascularization. Vascular Health and Risk Management. 2005;4:277-290
- Gondhowiardjo, S. 2005. *Disregulasi Proses Proliferasi Sel Kanker*. In: The 8<sup>th</sup> Course & Workshop Basic Science in Oncology. Modul A putaran ke-3. Jakarta
- Gavalas NG, Lontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, Dimopoulos MA, Bamias A. Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer. *Int. J. Mol. Sci.* 2013, 14.
- Gordon JD, Mesiano S, Zaloudek C.J, et al. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996;81:353–9.
- Hall, A. The role of angiogenesis in cancer. *Comp. Clin. Path.* 2005, 13, 95–99
- Hicklin DJ, Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23:1011-1027.

Hanahan D, Weinberg R.A. Hallmark of Cancer: The Next generation. Cell 144, March 4, 2011. Elsevier Inc.

Harlozinska A, Sedlaczek P, Kulpa J, Grybos M. Vascular Endothelial Growth Factor (VEGF) Concentration in Sera and Tumor Effusions from patients with ovarian carcinoma. Anti cancer Research 2004;24:1149-1158

Hiromitsu Yabushita, Mitsuma Shimazu, Mari Noguchi et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Spandidos Publications: Oncology Reports, Vol 10, Jan 2013, p.89-95

Indonesian Society of Gynecologic Oncology (INASGO), National Data 2013-2014

Ishioka Si, Sagae S, Terasawa K, Sugimura M, Nishioka Y, Tsukada K, Kudo R. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol. 2003; 89: 447-452.

Jemal A, Thomas A, Murray T. Cancer statistics. CA Cancer J 2002;52: 23–47.

Kommoss, S., Schmidt, D., Hedderich, J., Harter, P., et al. . Histological Grading in a Large Series of Advanced Stage Ovarian Carcinomas by Three Widely Used Grading Systems Consistent Lack of Prognostic Significance. Virchows Arch, 2009;454:249-256.

Kumar, V., Robbins, Leonard, S. Neoplasia in: Robbins & Cotran Pathologic Basis of Disease, 8th ed. Philadelphia: Saunders Elsevier, 2010:p. 269-342.

Kurman RJ, Shih Ie M: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011, 42:918-931.

Lauchlan SC: The secondary Mullerian system. Obstet Gynecol Surv 1972, 27:133-146.

Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008 Nov 10;26(32):5284-93.

Liekens S, Clercq ED, Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 2001; 61: 253–70

Li Jie, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent

- concepts on its origin and carcinogenesis. *Journal of Hematology & Oncology* 2012, 5:8.
- Li li, Wang L, Zhang W, Tang B, et al. Correlation of Serum VEGF Levels with Clinical Stage, Therapy Efficacy, Tumor Metastasis and Patient Survival in Ovarian Cancer. *Anti Cancer Research* 24: 1973-1980 (2004)
- Mabuchi S, Wakabayashi A, Kimura T. VEGF Targeting Agents in Ovarian Cancer, *Ovarian Cancer - Basic Science Perspective*, Dr. Samir Farghaly (Ed.), 2012. ISBN: 978-953-307-812-0, InTech. Available from: <http://www.intechopen.com/books/ovarian-cancer-basic-science-perspective/vegf-targetingtherapy-in-ovarian-cancer>
- Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am J Surg Pathol* 2006, 30:230-236
- Mesiano, S., Ferrara N, Jaffe R.B. Role of Vascular Endothelial Growth Factor in Ovarian Cancer. *Am J Pathol.* 1998;153:1249-1256.
- Naufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial Growth Factor (VEGF) and its Receptor. *FASEB J.* 1999; 13: 9-22.
- NICE clinical guideline 122. Ovarian Cancer. The recognition and initial management of ovarian cancer, April 2011.
- Pang R, Poon R. Clinical application of angiogenesis in cancers. *Vascular Health and Risk Management. Review.* Dove Medical Press, 2006.
- Plank MJ, Sleeman BD. Tumour-induced angiogenesis: a review. *J. Theo. Med.* 2004; 5: 137-53
- Polverini PJ. Angiogenesis in health and disease : insight into basic mechanisms and therapeutic opportunities. *J Dental Edu.* 2002; 66: 962-75.
- Roskoski, R., Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. *Crit. Rev. Oncol. Hematol.* 2007, 62, 179-213.
- Royal College of Obstetricians and Gynecologists. Targeted Therapies for the Management of Ovarian Cancer. September 2013.
- Rudlowski, C., Pickart, AK., Fuhljahn, C., Friepoertner, T, Schlehe B, Biesterfeld S, Schroeder W. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. *Int J Gynecol*

Cancer 2006, 16 (Suppl. 1), 183–189

Sato Y, Shimamoto T, Amada S, Asada Y, Hayashi T. Prognostic value of histologic grading of ovarian carcinomasnt J Gynecol Pathol. 2003 Jan;22(1):52-6.

Schorge, J.O., Schaffer, J.I., Halvorson, L.M., Hoffman, B.L., Bradshaw, K.D., Cunningham, F.G. 2008. Epithelial Ovarian Cancer, Ovarian Germ Cell and Sex Cord-Stromal Tumors. In: Schorge, J.O., Schaffer, J.I., Halvorson, L.M., Hoffman, B.L., Bradshaw, K.D., Cunningham, F.G. Williams Gynecology. Texas: The McGraw-Hill Companies Inc. Section 4, Chapter 35-36.

Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology, 1998; Fascicle 23, 3rd series

Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG (1998). Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893-901

Siegel RL, Miller KD, Jemal A. Cancer Statistic 2016. CA CANCER J CLIN 2016;66:7–30

Steel, RGD and Torrie, JH: Principles and Procedures of Statistics, 2<sup>nd</sup> Edition, McGraw-Hill Book Company, New York, 1980, pp 113-119

Sudoyo, A.W. 2005. Onkogen. In: Sudoyo, A.W. The 8th Course and Workshop Basic Science in Oncology. Modul A putaran ke-3, Jakarta

Tang L, Zheng M, Xiong Y, Ding H, et al . Clinical characteristics and prognosis of epithelial ovarian cancer in young women. Ai Zheng. 2008 Sep;27(9):951-5.

Tavasolli, F.A. &Devilee, P. 2003. Tumours of the Ovary and Peritoeum. Lyon: IARC Press, p. 113-202

Terman, B, Stoletov, K, 2001. VEGF and Tumor Angiogenesis. Einstein Quart, J.Biol and Med. 18: 59-66.

Tortora,G., Ciardiello,F. (2004). Angiogenesis : A Target for Cancer Therapy. Current Pharmaceutical Design. 10:11-26

Vang, R., Shih, I., Kurman, R.J. Ovarian Low-grade and High-grade Serous Carcinoma; Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems. *AdvAnatPathol*, 2009;16: 267-282.

Wheeler, J.E. Histopathology of Ovarian Cancer. In: Rubin, S.C., Sutton, G.P. (editor). *Ovarian Cancer*. 2nd Ed. Philadelphia: Lippincott Williams & Wilkins, 2001.

World Cancer Research Fund, American Institute For Cancer Research. Continuous Update Project. *Ovarian Cancer 2014 Report*.

Widhihastuti YS. Hubungan Ekspresi Vascular Endothelial Growth Factor-A (VEGF A) dengan Derajat Histopatologi dan Potensi Metastasis Karsinoma Ovarium. *Majalah Patologi Indonesia*, 2011;Vol.20, No.1.

Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer

Yamamoto S, Konishi I, Mandai M, Kuroda A, et all. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

Yephia M., Abu Seeda M., Kamal K., El Lamie I., Hassan M., Shafik A., Kassim G. Prognostic Value of Serum Vascular Endothelial Growth Factor (VEGF) in Women with Ovarian Cancer. *Journal of American Science* 2014;10 (1).

